MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer

Hiroki Ozawa,Naoki Haratake,Ayako Nakashoji,Tatsuaki Daimon,Atrayee Bhattacharya,Keyi Wang,Keisuke Shigeta,Atsushi Fushimi,Kazumasa Fukuda,Yohei Masugi,Ryo Yamaguchi,Minoru Kitago,Hirofumi Kawakubo,Yuko Kitagawa,Donald Kufe
DOI: https://doi.org/10.3390/biomedicines12071509
IF: 4.757
2024-07-08
Biomedicines
Abstract:Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There is no known involvement of MUC1-C in pNET progression. The present work was performed to determine if MUC1-C represents a potential target for advancing pNET treatment. We demonstrate that the MUC1 gene is upregulated in primary pNETs that progress with metastatic disease. In pNET cells, MUC1-C drives E2F- and MYC-signaling pathways necessary for survival. Targeting MUC1-C genetically and pharmacologically also inhibits self-renewal capacity and tumorigenicity. Studies of primary pNET tissues further demonstrate that MUC1-C expression is associated with (i) an advanced NET grade and pathological stage, (ii) metastatic disease, and (iii) decreased disease-free survival. These findings demonstrate that MUC1-C is necessary for pNET progression and is a novel target for treating these rare cancers with anti-MUC1-C agents under clinical development.
What problem does this paper attempt to address?